Reviewer's report

Title: Sitagliptin is effective and safe with type 1 or type 2 diabetic patients without endogenous insulin secretion: a case report

Version: 1 Date: 14 November 2010

Reviewer: Naoki Takeda

Which of the following best describes what type of case report this is?: An unexpected event in the course of observing or treating a patient

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

-This manuscript describes 3 cases where sitagliptin was effective in reducing A1c with patients who have no residual beta-cell function (no insulin secretion).

-The focus and data in the paper are not only clinically useful but also scientifically important. The discussion is well written and logical. However, the number of patients (only 3) was small and the study was not randomized, controlled or double-blinded as acknowledged by the author. As such it is a weak study to draw any strong conclusions. Therefore, please revise this over-riding conclusion and the title of the paper accordingly.

-Multiple mechanisms, for example exercise and diet management, may influence in A1c in addition to the pharmacological agencies used in this study.
Please discuss this.

-The strengths and limitations of the study should be mentioned.

**Quality of written English:** Needs some language corrections before being published

**Declaration of competing interests:**

I declare that I have no competing interests.